Endocyte Inc.

Merck's exit pushes Endocyte shares lower

June 18, 2014
 IBJ Staff
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
More

Life sciences critical mass elusive in Indiana after years of effortRestricted Content

May 10, 2014
J.K. Wall
Attempts to build the sector are making headway, but Indiana still lags leading states.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Endocyte raises another $100M in stock offering

April 7, 2014
J.K. Wall
Another public stock offering by the West Lafayette-based drugmaker swells its war chest for cancer drug development to $225 million.
More

Cancer treatment makes Endocyte premium takeover target

March 28, 2014
Bloomberg News
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
More

Analysts: Endocyte likely to receive green light on first drug this month

March 3, 2014
J.K. Wall
The European Committee for Medicinal Products for Human Use is scheduled to meet March 17-20, and analysts expect the agency to vote during that meeting to approve vintafolide, Endocyte’s first drug, which treats ovarian cancer.
More

Endocyte files to sell up to $60M in new stock

December 30, 2013
J.K. Wall

Endocyte Inc. plans to raise as much as $60 million by offering new shares to the public “from time to time,” to help it develop additional drugs.

More

Analysts: Investors wrong to dump Endocyte

October 14, 2013
J.K. Wall
Investors on Friday dumped shares of West Lafayette-based Endocyte Inc. after an independent analysis said an experimental lung cancer drug is unlikely to be declared superior to existing chemotherapy. But two analysts say, to the contrary, the analysis shows the prospects for Endocyte’s drug are as good as ever.
More

PANEL: Life sciences will see radically different futureRestricted Content

May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.

Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.

The following is an unedited transcript of the discussion.

More

Q&A

March 11, 2013
J.K. Wall
Mike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
More

Endocyte stock sinks due to possible drug-filing delay

February 26, 2013
J.K. Wall
Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer drug could be delayed another 10 months.
More

PROXY CORNER: Endocyte Inc.Restricted Content

May 12, 2012
West Lafayette-based Endocyte Inc. is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases.
More

Endocyte pulls trigger on European drug submission

March 13, 2012
J.K. Wall
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
More

Endocyte stays course despite being battered by investorsRestricted Content

December 31, 2011
J.K. Wall
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
More

Cancer-drug firm Endocyte to build commercial team in IndianapolisRestricted Content

November 12, 2011
J.K. Wall
Endocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year and a half as it anticipates approval of its ovarian cancer medication in Europe.
More

Drug shortages hit Lilly, Endocyte

November 7, 2011
J.K. Wall
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
More

Endocyte's potential enthralls investorsRestricted Content

May 7, 2011
Chris O'Malley
Shares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common wisdom is it won’t see sales from its first cancer drug until 2014.
More

PROXY CORNER: Endocyte Inc.

April 30, 2011
 IBJ Staff
West Lafayette-based Endocyte Inc. is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases.
More

Repeated price cuts take glow off Endocyte IPORestricted Content

February 12, 2011
Greg Andrews
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
More

Endocyte prices IPO stock

January 14, 2011
J.K. Wall
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
More

Endocyte's $86M IPO plan a boon for Indiana, investors

August 28, 2010
Greg Andrews
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital, Clarian Health Ventures and the Indiana Future Fund.
More

Cancer drug developer Endocyte files for IPO

August 18, 2010
Scott Olson
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet to be determined.
More

Health care venture capital swoons in Indy, holds steady statewide

February 6, 2010
 IBJ Staff
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
More

Endocyte, Purdue develop prostate cancer treatment device

July 13, 2009
 IBJ Staff
Purdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed a prostate cancer “homing device” to help anti-cancer agents specifically target prostate cancer tumors.

More
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT